BSP Pharmaceuticals vs WuXi Biologics: CDMO Comparison
How does BSP Pharmaceuticals compare to WuXi Biologics for ADC manufacturing?
Side-by-side comparison of BSP Pharmaceuticals and WuXi Biologics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- BSP Pharmaceuticals has materially broader EMA GMP coverage (15 active certificates vs 3) — stronger EU footprint.
- WuXi Biologics maintains 1 MHRA / UK GMP certificate; BSP Pharmaceuticals does not.
On a 13-modality CDMO landscape, both BSP Pharmaceuticals and WuXi Biologics qualify as ADC manufacturers; WuXi Biologics carries the higher composite Signal Score for ADC programs in this comparison.
What to evaluate for ADC programs
Both BSP Pharmaceuticals and WuXi Biologics qualify as ADC CDMOs. When choosing between them for ADC programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
HPAPI containment
Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work.
Linker-payload chemistry on file
Match the CDMO's payload + linker experience to your program. MMAE / vc-MMAE is the most common; PBDs, calicheamicin, Dxd-class topoI inhibitors, and TLR agonists each carry distinct handling and analytical demands.
Commercial bioconjugation track record
Has the CDMO conjugated a commercially-approved ADC? Track record on Polivy, Padcev, Trodelvy, Enhertu, Tivdak, Elahere, Adcetris, Mylotarg, Besponsa, Lumoxiti, Blenrep, etc. is a strong qualifying signal.
Integrated DS + DP
Bioconjugation produces ADC drug substance; you'll also need sterile fill-finish for drug product. Confirm whether the CDMO covers both or partners — both routes work, but integrated is faster on transfer.
Frequently asked: BSP Pharmaceuticals vs WuXi Biologics
How does BSP Pharmaceuticals compare to WuXi Biologics for ADC manufacturing?
On CDMO Signal's composite Signal Score, BSP Pharmaceuticals is 78/100 and WuXi Biologics is 83/100; BSP Pharmaceuticals has 1 FDA inspection on record vs 1 for WuXi Biologics; European coverage is 15 active EMA+MHRA certificates for BSP Pharmaceuticals vs 4 for WuXi Biologics. Both are tracked in the CDMO Signal directory as ADC CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, BSP Pharmaceuticals or WuXi Biologics?
Both BSP Pharmaceuticals and WuXi Biologics maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. BSP Pharmaceuticals has 1 FDA inspection on record; WuXi Biologics has 1.
How do BSP Pharmaceuticals and WuXi Biologics compare on European GMP coverage?
BSP Pharmaceuticals holds 15 active EMA GMP certificates and 0 MHRA / UK certificates. WuXi Biologics holds 3 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for ADC manufacturing — BSP Pharmaceuticals or WuXi Biologics?
Both BSP Pharmaceuticals and WuXi Biologics are tagged as ADC CDMOs in our directory, so both are credible options for ADC programs. The most important differentiator for ADC selection is typically hpapi containment: Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
BSP Pharmaceuticals carries a Signal Score of 78/100 and WuXi Biologics carries 83/100 — essentially tied for WuXi Biologics. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →